NeuroneticsFRA:NRC +3.94%51 EBITDA Margin % is -22.55% as of Mar. 2026. GuruFocus rates FRA:NRC with a GF Score™ of 51/100 and a GF Value™ of €1.63 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Neuronetics ranks worse than 71.08% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Neuronetics's EBITDA for the
three
months ended in Mar. 2026 was €-6.7 Mil. Neuronetics's Revenue for the
three
months ended in Mar. 2026 was €29.8 Mil. Therefore, Neuronetics's EBITDA margin for the quarter that ended in Mar. 2026 was -22.55%.
Neuronetics (FRA:NRC) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Neuronetics EBITDA Margin % Related Terms
Neuronetics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Neuronetics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NRC vs ZOMDF, RPID, OM: EBITDA Margin % Comparison
For the Medical Devices subindustry, Neuronetics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuronetics EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neuronetics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Neuronetics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuronetics (FRA:NRC) has a EBITDA Margin % of -22.55% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neuronetics and its competitors. According to the industry distribution chart, Neuronetics ranks #580 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 71.1%.
Is Neuronetics' EBITDA Margin % too high?
Neuronetics' current EBITDA Margin % is -22.55%. Based on the distribution chart, Neuronetics ranks #580 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Neuronetics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Neuronetics' EBITDA Margin % compare to ZOMDF and RPID?
According to the Medical Devices & Instruments industry distribution chart, Neuronetics ranks #580 out of 816 companies for EBITDA Margin %. This places Neuronetics in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neuronetics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuronetics's current EBITDA Margin % is -22.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuronetics stock overvalued right now?
Based on GuruFocus' analysis, Neuronetics (FRA:NRC) is currently considered Possible Value Trap. The stock's GF Value™ is €1.63, compared to a current price of €1.06 — trading 35.3% below its estimated fair value. The current EBITDA Margin % is -22.55%. Neuronetics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Neuronetics (FRA:NRC), the current EBITDA Margin % is -22.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuronetics (FRA:NRC) Overvalued in 2026?
Based on GuruFocus' analysis, Neuronetics stock appears to be undervalued.
The current stock price of €1.06 is trading 35.3% below its estimated GF Value™ of €1.63.
GuruFocus considers Neuronetics to be Possible Value Trap.
Key valuation signals for FRA:NRC:
EBITDA Margin %: -22.55%
GF Value™: €1.63 vs. price of €1.06 (35.3% below fair value)
No single metric tells the full story. See the FRA:NRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
51GF Score
Get the complete analysis for FRA:NRC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NRC has been successfully added to your 
